California is currently home to 5595 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Recruiting
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Stanford Cancer Center, Palo Alto, California
Conditions: Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: TOI Clinical Research, Cerritos, California
Conditions: HER2-positive Advanced Solid Tumor
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
Recruiting
This phase II trial studies how well pembrolizumab with or without standard of care axitinib works in treating patients with clear cell kidney cancer that has spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic) who are undergoing surgery. Pembrolizumab is an antibody that is designed to bind to and block the activity of PD-1, a molecule in the body that may be responsible for inhibiting the body's immune response against cancer cells. Axitinib is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma
ABC-CT Pre-School Feasibility Study
Recruiting
This is a multicenter study that aims to determine whether the EEG and ET experiments studied in the ABC-CT Phase 1 and ABC-CT Confirmation studies can be successfully used with 3-5-year-old children and to determine the viability of these measures as potential biomarkers in 3-5-year-old children with ASD. Blood (DNA) samples will be collected from participants with ASD and biological parents for future genomic analyses, and raw, processed, and analyzed data will be shared to create a community... Read More
Gender:
ALL
Ages:
Between 3 years and 5 years
Trial Updated:
10/01/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Autism Spectrum Disorder
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
Recruiting
This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body (metastatic) and has limited disease progression (oligoprogression). Currently, the standard of care for breast cancer patients with oligoprogressive disease is to change systemic therapy when progression occurs. Radiation therapy uses high energy x-rays, particles, or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: University of California San Francisco (UCSF), San Francisco, California
Conditions: Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/01/2024
Locations: UCLA Westwood, Los Angeles, California
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
Recruiting
This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment with antiandrogen therapy (ADT) combination therapy. Combination treatment including ADT plus chemotherapy and androgen receptor (AR) targeted therapy or ADT plus AR targeted therapies work... Read More
Gender:
MALE
Ages:
60 years and above
Trial Updated:
10/01/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
Recruiting
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: OP-1250 in combination with everolimus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: University of California San Francisco Health, San Francisco, California
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Breast Cancer
Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer
Recruiting
This clinical trial investigates how practical and doable (feasibility) cell-free deoxyribonucleic acid (DNA) liquid biopsy is in screening high-risk patients for lung cancer. Currently, a low dose computed tomography (CT) scan is used to screen for lung cancer, however, due to various factors, few high-risk patients are screened. Liquid biopsy utilizes technology that can detect small amounts of DNA shed by cancer cells and may be able to spot lung cancer at an earlier stage. If a positive resu... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
10/01/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Lung Carcinoma
Personalized Perioperative Analgesia Platform (PPAP) for Pediatric Spine Fusion Surgery (sIRB)
Recruiting
The purpose of this collaborative CTSA application is to develop an innovative perioperative precision analgesia platform (PPAP) to improve analgesia and reduce serious immediate and long-term adverse outcomes of perioperative opioids in children undergoing painful surgery.
Gender:
ALL
Ages:
Between 10 years and 21 years
Trial Updated:
10/01/2024
Locations: University of California, San Francisco, California
Conditions: PPAP, Spine Fusion
Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Recruiting
AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Advanced Solid Tumor